1. Home
  2. NEXM vs MAIA Comparison

NEXM vs MAIA Comparison

Compare NEXM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXM

NexMetals Mining Corp.

HOLD

Current Price

$3.11

Market Cap

83.8M

Sector

N/A

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.30

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXM
MAIA
Founded
N/A
2018
Country
Canada
United States
Employees
204
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.8M
77.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NEXM
MAIA
Price
$3.11
$1.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
42.2K
585.8K
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$0.87
52 Week High
$6.75
$3.19

Technical Indicators

Market Signals
Indicator
NEXM
MAIA
Relative Strength Index (RSI) 61.60 44.39
Support Level $3.06 $1.20
Resistance Level $4.03 $1.46
Average True Range (ATR) 0.24 0.09
MACD 0.08 0.01
Stochastic Oscillator 83.02 33.19

Price Performance

Historical Comparison
NEXM
MAIA

About NEXM NexMetals Mining Corp.

NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: